Business Wire

NTT-COMMUNICATIONS

8.4.2021 04:02:11 CEST | Business Wire | Press release

Share
NTT Com’s Prototype Platform Securely Shares CO2 Emissions-related Data from Switzerland to Sites in Germany and Japan

NTT Communications Corporation (NTT Com), the ICT solutions and international communications business within the NTT Group, announced today that it has succeeded in a trial sharing of production-line data related to CO2 emissions via a prototype platform that enables interconnection via IDS standards which support data sovereignty in GAIA-X data ecosystem. The trial data, which normally would not be available for sharing due to its high confidentiality even though partners engaged in actual business would need to perform CO2 emissions calculations, was transmitted securely to designated sites in Germany and Japan from Switzerland Innovation Park Biel/Bienne in Switzerland.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210407006040/en/

GAIA-X is an initiative announced by the German and French governments in October 2019 to support data sharing via infrastructure that ensures data protection, transparency, reliability and interoperability to protect the rights of European companies, governments, institutions and citizens.

NTT Com conducted the trial under the assumption that such data will be used by companies engaged in actual business to review their manufacturing methods to achieve greater decarbonization. The prototype platform, which enables interconnection with IDS Connectors, also is equipped with DATA Trust® , a mechanism for the secure sharing of highly confidential data.

The trial involved the sharing of electricity-consumption data that business partners typically would use to calculate CO2 emissions generated during the manufacturing of specific products. The trial confirmed that NTT’s platform can share such data securely with only those parties permitted by law or contract.

The prototype was developed using Nippon Telegraph and Telephone Corporation (Software Innovation Center)'s business-to-business data distribution technology, in cooperation with Robot Revolution & Industrial IoT Initiative (RRI), International Data Spaces Association (IDSA), Fraunhofer-Gesellschaft, Switzerland Innovation Park Biel/Bienne and Japan Innovation Park.

NTT Com plans to exhibit the trial results at the joint booth of IDSA and RRI during the Hannover Messe industrial fair in Germany from April 12-16.

“Japan is very close to Europe in the field of industry, with a strong experience in automotive, steel, or manufacturing,” said Hubert Tardieu, Chairman of GAIA-X AISBL. “The main objective in every industry is nowadays data sharing and service orchestration like in GAIA-X. NTT Communications starts with a first run in data sharing between, Japan, Germany and Switzerland, using the IDS standard which supports data sovereignty in GAIA-X data ecosystems. We are proud at GAIA-X AISBL to strongly support the launching of the japan Hub trough NTT Communications and start more use cases around GAIA-X.”

Going forward, NTT Com will build a test environment in Japan to connect with GAIA-X and start interoperability tests with multiple partner companies around the world this summer. If all goes well, NTT Com hopes to launch an official platform within the fiscal year ending in March 2022. The launch would be coordinated with organizations and groups involved with international data distribution, including Data Society Alliance, OPC Foundation Japan, RRI, GAIA-X AISBL and IDSA.

Data utilization has become indispensable for initiatives such as global decarbonization, the early achievement of the United Nations’ Sustainable Development Goals and the strengthening of industries. At the same time, however, legal systems and technologies to regulate and manage data use are being developed around the world, one of which is GAIA-X, to prevent the leakage of corporate and national secrets and to protect data sovereignty.

In the future, it is expected that companies will be required to use GAIA-X to send and receive highly confidential data to and from business partners in European countries. This means that companies unable to use GAIA-X would not be able to do business with European partners if sensitive data sharing were involved. NTT Com’s envisioned platform, however, would enable such companies to easily connect to GAIA-X without have to spend valuable time and money on an acceptable data-sharing solution.

About NTT Communications

NTT Communications solves the world's technology challenges by helping enterprises overcome complexity and risk in their ICT environments with managed IT infrastructure solutions. These solutions are backed by our worldwide infrastructure, including industry leading, global tier-1 public and private networks reaching over 190 countries/regions, and more than 500,000m2 of the world's most advanced data center facilities. Our global professional services teams provide consultation and architecture for the resiliency and security required for your business success, and our scale and global capabilities in technology world are unsurpassed. Combined with NTT Ltd., NTT Data, and NTT DOCOMO, we are NTT Group.
www.ntt.com | Twitter@NTT Com | Facebook@NTT Com | LinkedIn@NTT Com

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye